Skip to main content
SpringerLink
Log in
Book cover

Personalized, Evolutionary, and Ecological Dermatology pp 1–18Cite as

Genetic Testing and Personalized Medicine in Dermatology

  • Chapter
  • First Online:

Abstract

The genetic basis of many dermatologic diseases is becoming increasingly apparent however its clinical application to an individual patient remains a challenge. This chapter aims to highlight the utility of genetic testing in the setting of screening, diagnosing and counseling patients. Gardner’s syndrome, Peutz-Jeghers syndrome, Cowden syndrome, MEN Syndromes, Ataxia Telangiectasia, Wiskott-Aldrich syndrome, Familial Mediterranean Fever are highlighted as examples of diseases with cutaneous findings where genetic knowledge can help guide clinical care.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ferris FFM. Ferri’s clinical advisor 2015: 5 books in 1. 1st ed. Philadelphia: Elsevier; 2015.

    Google Scholar 

  2. Bisgaard ML, Bulow S. Familial adenomatous polyposis (FAP): genotype correlation to FAP phenotype with osteomas and sebaceous cysts. Am J Med Genet A. 2006;140(3):200–4.

    Article  PubMed  Google Scholar 

  3. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol. 2006;101(2):385–98.

    Article  PubMed  Google Scholar 

  4. Syngal S, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62; quiz 263.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Vasen HF, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut. 2008;57(5):704–13.

    Article  CAS  PubMed  Google Scholar 

  6. Bjork JA, et al. Risk factors for rectal cancer morbidity and mortality in patients with familial adenomatous polyposis after colectomy and ileorectal anastomosis. Dis Colon Rectum. 2000;43(12):1719–25.

    Article  CAS  PubMed  Google Scholar 

  7. Bulow S. Results of national registration of familial adenomatous polyposis. Gut. 2003;52(5):742–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Heiskanen I, Luostarinen T, Jarvinen HJ. Impact of screening examinations on survival in familial adenomatous polyposis. Scand J Gastroenterol. 2000;35(12):1284–7.

    Article  CAS  PubMed  Google Scholar 

  9. Parc YR, et al. Familial adenomatous polyposis: prevalence of adenomas in the ileal pouch after restorative proctocolectomy. Ann Surg. 2001;233(3):360–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Groves CJ, et al. Prevalence and morphology of pouch and ileal adenomas in familial adenomatous polyposis. Dis Colon Rectum. 2005;48(4):816–23.

    Article  PubMed  Google Scholar 

  11. Friederich P, et al. Risk of developing adenomas and carcinomas in the ileal pouch in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2008;6(11):1237–42.

    Article  PubMed  Google Scholar 

  12. Tajika M, et al. Prevalence of adenomas and carcinomas in the ileal pouch after proctocolectomy in patients with familial adenomatous polyposis. J Gastrointest Surg. 2009;13(7):1266–73.

    Article  PubMed  Google Scholar 

  13. Campos FG, et al. Rectal and pouch recurrences after surgical treatment for familial adenomatous polyposis. J Gastrointest Surg. 2009;13(1):129–36.

    Article  PubMed  Google Scholar 

  14. Ooi BS, et al. Anal transitional zone cancer after restorative proctocolectomy and ileoanal anastomosis in familial adenomatous polyposis: report of two cases. Dis Colon Rectum. 2003;46(10):1418–23; discussion 1422–3.

    Article  PubMed  Google Scholar 

  15. Tulchinsky H, et al. Extracolonic manifestations of familial adenomatous polyposis after proctocolectomy. Arch Surg. 2005;140(2):159–63; discussion 164.

    Article  PubMed  Google Scholar 

  16. Church J. Ileoanal pouch neoplasia in familial adenomatous polyposis: an underestimated threat. Dis Colon Rectum. 2005;48(9):1708–13.

    Article  PubMed  Google Scholar 

  17. NCCN clinical practice guidelines. 3 May 2015.

    Google Scholar 

  18. Herraiz M, et al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol. 2007;5(3):367–73.

    Article  PubMed  Google Scholar 

  19. Giardiello FM, et al. Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. Gut. 1996;39(6):867–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. van Lier MG, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105(6):1258–64; author reply 1265.

    Article  PubMed  Google Scholar 

  21. Lim W, et al. Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology. 2004;126(7):1788–94.

    Article  CAS  PubMed  Google Scholar 

  22. van Lier MG, et al. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut. 2011;60(2):141–7.

    Article  PubMed  Google Scholar 

  23. Resta N, et al. Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study. Dig Liver Dis. 2013;45(7):606–11.

    Article  CAS  PubMed  Google Scholar 

  24. Giardiello FM, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119(6):1447–53.

    Article  CAS  PubMed  Google Scholar 

  25. Utsunomiya J, et al. Peutz-Jeghers syndrome: its natural course and management. Johns Hopkins Med J. 1975;136(2):71–82.

    CAS  PubMed  Google Scholar 

  26. Jewel Samadder N, Kory M, Jasperson W. In: Intestinal Polyposis Syndromes. Switzerland: Springer International Publishing; 2015.

    Google Scholar 

  27. Hinds R, et al. Complications of childhood Peutz-Jeghers syndrome: implications for pediatric screening. J Pediatr Gastroenterol Nutr. 2004;39(2):219–20.

    Article  CAS  PubMed  Google Scholar 

  28. van Lier MG, et al. High cumulative risk of intussusception in patients with Peutz-Jeghers syndrome: time to update surveillance guidelines? Am J Gastroenterol. 2011;106(5):940–5.

    Article  PubMed  Google Scholar 

  29. Cunningham JD, et al. The role of laparoscopy in the management of intussusception in the Peutz-Jeghers syndrome: case report and review of the literature. Surg Laparosc Endosc. 1998;8(1):17–20.

    Article  CAS  PubMed  Google Scholar 

  30. Lebwohl M. Peutz-Jeghers syndrome. In: Treatment of skin disease comprehensive therapeutic strategies. Philadelphia: Elsevier; 2014.

    Google Scholar 

  31. Hernan I, et al. De novo germline mutation in the serine-threonine kinase STK11/LKB1 gene associated with Peutz-Jeghers syndrome. Clin Genet. 2004;66(1):58–62.

    Article  CAS  PubMed  Google Scholar 

  32. Beggs AD, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut. 2010;59(7):975–86.

    Article  CAS  PubMed  Google Scholar 

  33. Mallory SB. Cowden syndrome (multiple hamartoma syndrome). Dermatol Clin. 1995;13(1):27–31.

    CAS  PubMed  Google Scholar 

  34. Monga E, et al. Multiple hamartoma syndrome: clinicoradiological evaluation and histopathological correlation with brief review of literature. Indian J Dermatol. 2014;59(6):598–601.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Marra G, et al. Cowden's disease with extensive gastrointestinal polyposis. J Clin Gastroenterol. 1994;18(1):42–7.

    Article  CAS  PubMed  Google Scholar 

  36. Starink TM, et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet. 1986;29(3):222–33.

    Article  CAS  PubMed  Google Scholar 

  37. Brownstein MH, Wolf M, Bikowski JB. Cowden's disease: a cutaneous marker of breast cancer. Cancer. 1978;41(6):2393–8.

    Article  CAS  PubMed  Google Scholar 

  38. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet. 2000;37(11):828–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Schreibman IR, et al. The hamartomatous polyposis syndromes: a clinical and molecular review. Am J Gastroenterol. 2005;100(2):476–90.

    Article  PubMed  Google Scholar 

  40. Nelen MR, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet. 1999;7(3):267–73.

    Article  CAS  PubMed  Google Scholar 

  41. Melbarde-Gorkusa I, et al. Challenges in the management of a patient with Cowden syndrome: case report and literature review. Hered Cancer Clin Pract. 2012;10:5.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Hammami S, et al. Managing the risk of cancer in Cowden syndrome: a case report. J Med Case Rep. 2012;6:225.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Tan MH, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Thakker RV. Multiple endrocrine neoplasia type I. In: Jameson J, De Groot L, editor. Endocrinology. Philadelphia: Elseivier; 2010. p. 2719–41.

    Google Scholar 

  45. Machens A, et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf). 2007;67(4):613–22.

    Google Scholar 

  46. Kann PH, et al. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer. 2006;13(4):1195–202.

    Article  CAS  PubMed  Google Scholar 

  47. Newey PJ, et al. Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2009;94(10):3640–6.

    Article  CAS  PubMed  Google Scholar 

  48. Brandi ML, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658–71.

    Article  CAS  PubMed  Google Scholar 

  49. Thomas-Marques L, et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol. 2006;101(2):266–73.

    Article  PubMed  Google Scholar 

  50. Gibril F, et al. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab. 2001;86(11):5282–93.

    Article  CAS  PubMed  Google Scholar 

  51. Thakker RV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011.

    Article  CAS  PubMed  Google Scholar 

  52. Trouillas J, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008;32(4):534–43.

    Article  PubMed  Google Scholar 

  53. Verges B, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002;87(2):457–65.

    Article  CAS  PubMed  Google Scholar 

  54. Sakurai A, et al. Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database. Clin Endocrinol (Oxf). 2012;76(4):533–9.

    Article  Google Scholar 

  55. Asgharian B, et al. Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin Cancer Res. 2004;10(3):869–80.

    Article  CAS  PubMed  Google Scholar 

  56. Degroot LJ, Jameson JL. 148 multiple endrocrine neoplasia type I. In: Endocrinology: adult and pediatric. Philadelphia: Saunders/Elsevier; 2010.

    Google Scholar 

  57. Marini F, Giusti F, Brandi ML. Genetic test in multiple endocrine neoplasia type 1 syndrome: an evolving story. World J Exp Med. 2015;5(2):124–9.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Howe JR, Norton JA, Wells Jr SA. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery. 1993;114(6):1070–7.

    CAS  PubMed  Google Scholar 

  59. Eng C, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575–9.

    Article  CAS  PubMed  Google Scholar 

  60. Lairmore TC, et al. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg. 1993;217(6):595–601; discussion 601–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Wray CJ, et al. Failure to recognize multiple endocrine neoplasia 2B: more common than we think? Ann Surg Oncol. 2008;15(1):293–301.

    Article  PubMed  Google Scholar 

  62. Brauckhoff M, et al. Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: An exploratory analysis. Surgery. 2008;144(6):1044–50; discussion 1050–3.

    Article  PubMed  Google Scholar 

  63. Lodish M. Multiple endocrine neoplasia type 2. Front Horm Res. 2013;41:16–29.

    Article  CAS  PubMed  Google Scholar 

  64. Moline J, Eng C. Multiple endocrine neoplasia type 2: an overview. Genet Med. 2011;13(9):755–64.

    Article  CAS  PubMed  Google Scholar 

  65. Skinner MA, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005;353(11):1105–13.

    Article  CAS  PubMed  Google Scholar 

  66. Chen H, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775–83.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Kloos RT, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612.

    Article  PubMed  Google Scholar 

  68. McKinnon PJ. ATM and ataxia telangiectasia. EMBO Rep. 2004;5(8):772–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Woods CG, Taylor AM. Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals. Q J Med. 1992;82(298):169–79.

    CAS  PubMed  Google Scholar 

  70. Crawford TO. Ataxia telangiectasia. Semin Pediatr Neurol. 1998;5(4):287–94.

    Article  CAS  PubMed  Google Scholar 

  71. Gatti RA, et al. The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta Stone. Clin Rev Allergy Immunol. 2001;20(1):87–108.

    Article  CAS  PubMed  Google Scholar 

  72. Sedgwick RP, Boder E. Ataxia-Telangiectasia. In: Handbook of clinical neurology. Philadelphia: Elsevier Publishing; Vol. 60. 1991. p. 347–423.

    Google Scholar 

  73. Lewis RF, Lederman HM, Crawford TO. Ocular motor abnormalities in ataxia telangiectasia. Ann Neurol. 1999;46(3):287–95.

    Article  CAS  PubMed  Google Scholar 

  74. Baloh RW, Yee RD, Boder E. Eye movements in ataxia-telangiectasia. Neurology. 1978;28(11):1099–104.

    Article  CAS  PubMed  Google Scholar 

  75. Gumy-Pause F, Wacker P, Sappino AP. ATM gene and lymphoid malignancies. Leukemia. 2004;18(2):238–42.

    Article  CAS  PubMed  Google Scholar 

  76. Angele S, et al. ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res. 2003;63(24):8717–25.

    CAS  PubMed  Google Scholar 

  77. Thorstenson YR, et al. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res. 2003;63(12):3325–33.

    CAS  PubMed  Google Scholar 

  78. Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood. 2013;121(20):4036–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Khanna KK, et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet. 1998;20(4):398–400.

    Article  CAS  PubMed  Google Scholar 

  80. Swift M, et al. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet. 1986;39(5):573–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Swift M, et al. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 1987;316(21):1289–94.

    Article  CAS  PubMed  Google Scholar 

  82. Massaad MJ, Ramesh N, Geha RS. Wiskott-Aldrich syndrome: a comprehensive review. Ann N Y Acad Sci. 2013;1285:26–43.

    Article  CAS  PubMed  Google Scholar 

  83. Sullivan KE, et al. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125(6 Pt 1):876–85.

    Article  CAS  PubMed  Google Scholar 

  84. Loyola Presa JG, et al. Cutaneous manifestations in patients with Wiskott-Aldrich syndrome submitted to haematopoietic stem cell transplantation. Arch Dis Child. 2013;98(4):304–7.

    Article  PubMed  Google Scholar 

  85. Modell V, et al. Global study of primary immunodeficiency diseases (PI)–diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51(1):61–70.

    Article  PubMed  Google Scholar 

  86. Litzman J, et al. Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome. Arch Dis Child. 1996;75(5):436–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet. 2014;7:55–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Mahlaoui N, et al. Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome. Blood. 2013;121(9):1510–6.

    Article  CAS  PubMed  Google Scholar 

  89. Ozsahin H, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood. 2008;111(1):439–45.

    Article  CAS  PubMed  Google Scholar 

  90. Antoine C, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99. Lancet. 2003;361(9357):553–60.

    Article  PubMed  Google Scholar 

  91. Gungor T, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383(9915):436–48.

    Article  CAS  PubMed  Google Scholar 

  92. Shohat M, Halpern GJ. Familial Mediterranean fever–a review. Genet Med. 2011;13(6):487–98.

    Article  PubMed  Google Scholar 

  93. Kucuk A, et al. Familial Mediterranean fever. Acta Medica (Hradec Kralove). 2014;57(3):97–104.

    Article  Google Scholar 

  94. Lidar M, et al. The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J Rheumatol. 2006;33(6):1089–92.

    PubMed  Google Scholar 

  95. Tunca M, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84(1):1–11.

    Article  Google Scholar 

  96. El-Shanti H, Majeed HA, El-Khateeb M. Familial mediterranean fever in Arabs. Lancet. 2006;367(9515):1016–24.

    Article  PubMed  Google Scholar 

  97. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17(1):25–31.

    Google Scholar 

  98. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell. 1997;90(4):797–807.

    Google Scholar 

  99. Giancane G, et al. Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis. 2015;74(4):635–41.

    Article  CAS  PubMed  Google Scholar 

  100. Stoffels M, et al. MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Ann Rheum Dis. 2014;73(2):455–61.

    Article  CAS  PubMed  Google Scholar 

  101. Ben-Chetrit E, Touitou I. Familial mediterranean Fever in the world. Arthritis Rheum. 2009;61(10):1447–53.

    Article  CAS  PubMed  Google Scholar 

  102. Onen F. Familial Mediterranean fever. Rheumatol Int. 2006;26(6):489–96.

    Article  PubMed  Google Scholar 

  103. Hentgen V, et al. Evidence-based recommendations for the practical management of Familial Mediterranean fever. Semin Arthritis Rheum. 2013;43(3):387–91.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Santa Barbara Cottage Hospital, 55 Fruit Street, BH616, Boston, MA, 02114, USA

    Rebecca Thiede MD

  2. Harvard Dermatology Department, Massachusetts General Hospital, 55 Fruit St, BH616, Boston, MA, 02114, USA

    Daniel Butler MD

Authors
  1. Rebecca Thiede MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Butler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Butler MD .

Editor information

Editors and Affiliations

  1. Department of Dermatology , Nova Southeastern Medical School, Ft. Lauderdale, Florida, USA

    Robert A. Norman

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Thiede, R., Butler, D. (2016). Genetic Testing and Personalized Medicine in Dermatology. In: Norman, R. (eds) Personalized, Evolutionary, and Ecological Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-41088-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-41088-3_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-41086-9

  • Online ISBN: 978-3-319-41088-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation